{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Bile samples were planned to be collected from participants in the pharmacokinetic/pharmacodynamic expansion cohort for analysis of GSK2816126 and its metabolites via the Entero-Test. Samples were not collected due to early termination of the study; therefore, no analysis could be performed.","groups":[{"description":"At maximum tolerated or recommended phase II dose, participants with GCB-DLBCL were enrolled in Part 1 expansion cohorts and received GSK2816126 twice-weekly, as intravenous solution.","id":"OG000","title":"Part 1: Participants With GCB-DLBCL"},{"description":"At maximum tolerated or recommended phase II dose, participants with solid tumors were enrolled in Part 1 expansion cohorts and received GSK2816126 twice-weekly, as intravenous solution.","id":"OG001","title":"Part 1: Participants With Solid Tumors"}],"populationDescription":"Pharmacokinetic Population. Samples were not collected due to early study termination.","reportingStatus":"POSTED","timeFrame":"Day 15","title":"Part 1: Concentration of GSK2816126 and Its Metabolites in Bile","type":"SECONDARY"}